



University of Groningen

Bronchial Provocation Testing Can Be Improved by Using Dry Powder Adenosine Instead of Nebulized Adenosine Monophosphate

Lexmond, Anne J.; Boudewijn, Ilse M.; Hagedoorn, Paul; Schokker, Siebrig; Cox, Claire A.; Vonk, Judith M.; ten Hacken, Nick H. T.; Frijlink, Henderik W.; Vroegop, Sebastiaan J.; van den Berge, Maarten

Published in:

American Journal of Respiratory and Critical Care Medicine

DOI:

[10.1164/rccm.201704-0715LE](https://doi.org/10.1164/rccm.201704-0715LE)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Final author's version (accepted by publisher, after peer review)

Publication date:

2018

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Lexmond, A. J., Boudewijn, I. M., Hagedoorn, P., Schokker, S., Cox, C. A., Vonk, J. M., ... van den Berge, M. (2018). Bronchial Provocation Testing Can Be Improved by Using Dry Powder Adenosine Instead of Nebulized Adenosine Monophosphate. *American Journal of Respiratory and Critical Care Medicine*, 197(3), 391-394. <https://doi.org/10.1164/rccm.201704-0715LE>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Bronchial provocation testing can be improved by using dry powder adenosine instead of nebulized AMP

Anne J. Lexmond¹, Ilse M. Boudewijn^{2,3}, Paul Hagedoorn¹, Siebrig Schokker⁴, Claire A. Cox^{2,3}, Judith M. Vonk^{3,5}, Nick H.T. ten Hacken^{2,3}, Henderik W. Frijlink¹, Sebastiaan J. Vroegop⁴, Maarten van den Berge^{2,3}

¹University of Groningen, Department of Pharmaceutical Technology and Biopharmacy;

²University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases;

³University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD;

⁴Martini Hospital Groningen, Department of Pulmonary Diseases

⁵University of Groningen, University Medical Center Groningen, Department of Epidemiology

Corresponding author:

Dr A.J. Lexmond

University of Groningen

Department of Pharmaceutical Technology and Biopharmacy (XB21)

9713 AV Groningen, The Netherlands

Tel: +3150-3633254; Fax: +3150-3632500; E-mail: a.j.lexmond@rug.nl

Funding: This research was supported by a research grant from TEVA Pharma. TEVA Pharma was in no way involved in study design, writing or reviewing of the manuscript.

To the editor:

Airway hyperresponsiveness (AHR) to adenosine has proven to be a good marker for eosinophilic airway inflammation in asthma and can be used to monitor disease activity and therapeutic effectiveness of inhaled corticosteroids (ICS) (1–3). Adenosine is usually administered by nebulization of adenosine monophosphate (AMP) but the highest feasible concentration of AMP often fails to induce sufficient bronchoconstriction in subjects with asthma (4,5). We studied whether this limitation can be resolved by administering adenosine as dry powder formulation. We have previously demonstrated the feasibility of this new bronchial provocation method in a small proof-of-concept study (6). The aim of the present study was to further validate the dry powder adenosine provocation test in a larger cohort of subjects with asthma.

Data were obtained from subjects recruited for the OLIVIA study (clinical trial number: NCT01741285, www.clinicaltrials.gov). Sixty current or ex-smokers with asthma (34 females, 26 males) with $FEV_1 \geq 50\%$ predicted, who did not use ICS for at least four weeks, underwent provocations with both AMP and dry powder adenosine as baseline measurements on subsequent visits (1–2 weeks apart), in addition to blood sampling, spirometry, body plethysmography, impulse oscillometry (IOS) and multiple breath nitrogen washout (MBNW) measurements. Their mean (\pm SD) age was 45 ± 12 years and baseline FEV_1 $89 \pm 16\%$ predicted.

AMP was administered by nebulization of doubling concentrations (0.04–320 mg/mL). Dry powder adenosine was administered with an investigational inhaler in doubling doses (0.04–80 mg) (6,7). We determined the provocative concentration (PC_{20}) of AMP and dose (PD_{20}) of adenosine causing the forced expiratory volume in 1 s (FEV_1) to drop with 20% by log-

linear interpolation and assessed which clinical characteristics were predictors of these parameters. Provocation tests were negative if no 20% drop in FEV₁ was reached after administration of the highest concentration/dose and values were censored to 640 mg/mL for PC₂₀ AMP and 160 mg for PD₂₀ adenosine for analysis. Calculations were performed with the base-2 logarithm (\log_2) of PC₂₀ AMP and PD₂₀ adenosine to reflect the use of doubling dose steps and normalize the distribution.

We calculated the agreement between the two tests with Cohen's kappa and correlation analysis. Correlation analysis was also performed to assess associations between subject baseline characteristics and PC₂₀ AMP/PD₂₀ adenosine. Associations with a *p*-value <0.20 were considered for multiple linear regression analysis, although per baseline measurement procedure maximally one (the most significant) predictor was included to prevent multicollinearity. Forced entry multiple linear regression analysis was performed to determine which parameters independently predict the airway responses.

Forty subjects reached the predefined 20% drop in FEV₁ on both AMP and adenosine. Ten subjects obtained a positive adenosine test (PD₂₀ 5.4–39 mg) but negative AMP test (PC₂₀ >320 mg/mL), whereas two subjects had a negative adenosine test (PD₂₀ >80 mg) but positive AMP test (PC₂₀ 143 and 148 mg/mL). Seven subjects did not reach a 20% drop in FEV₁ on either stimulus. One subject, who had a negative AMP test, experienced severe cough during inhalation of dry powder adenosine, leading to early termination of the test. The total percentage of non-responders was 30% (18 out of 60) for AMP and 15% (9 out of 59) for adenosine. Figure 1A shows PC₂₀ AMP and PD₂₀ adenosine values, clearly illustrating the higher responder rate to adenosine. PC₂₀ AMP and PD₂₀ adenosine were strongly correlated

($r_{Sp} = 0.799$; Figure 1B), yet had only a moderate agreement ($\kappa = 0.42$), mainly due to the larger number of non-responders to AMP.

Baseline variables included in multiple linear regression analysis for PC₂₀ AMP were age, smoking status, blood eosinophils, FEV₁, residual volume (RV), and the ventilation heterogeneity of the conductive lung zone (S_{cond}). For PD₂₀ adenosine these were age, blood eosinophils, FEV₁, and RV. The models obtained by multiple regression analysis were largely similar for PC₂₀ AMP and PD₂₀ adenosine with predictive powers of 34% and 30% respectively (Table 1). Only age (AMP and adenosine) and FEV₁ (adenosine) were found to be independent predictors ($p < 0.05$). Age and FEV₁ were positively associated with both PC₂₀ AMP and PD₂₀ adenosine, whereas blood eosinophils and RV exhibited a trend towards an inverse association.

The present work shows that bronchial provocation with dry powder adenosine is a suitable method for measuring AHR in asthmatic subjects. Moreover, the new test method allowed us to administer higher doses, resulting in fewer false negative test results, while the degree of AHR to dry powder adenosine correlated well with the degree of AHR to nebulized AMP. Despite the greater sensitivity, there were still nine subjects with a negative dry powder adenosine provocation test. Although the order of provocation testing was performed non-randomized with AMP first and dry powder adenosine second one to two weeks later and refractoriness has been shown to occur after AMP provocation (8), we consider any remaining effect one to two weeks later to be unlikely given the findings of Singh et al. (9). Some patients may have developed a component of COPD or asthma-COPD overlap, since this study examined current or former smokers. There was, however, no relationship apparent between measures of airway obstruction at baseline and PD₂₀ adenosine (e.g. only two out of

nine had an FEV₁/FVC ratio <70%) or with their smoking status (four current and five former smokers). Therefore, we expect that increasing the top dose, which was now arbitrarily chosen at 80 mg, could further reduce the number of false negatives and thus increase the test's sensitivity even more. However, it cannot be ruled out that there may actually be subjects with asthma that remain unresponsive to even higher doses inhaled adenosine, which requires further investigation.

The subjects did not appear to react more severely to dry powder adenosine than anticipated from their responsiveness to AMP, indicating that the test is safe to use. Severe cough, a side effect that has been shown to hinder applicability of the mannitol provocation test (10), another indirect measure of AHR, was only reported in one subject. No other side effects were observed.

We previously reported that AHR to AMP is associated with eosinophilic inflammation (1). In the present study, blood eosinophils were included in the prediction models, although their individual contributions were not significant for either PC₂₀ AMP or PD₂₀ adenosine ($p = 0.066$ and $p = 0.11$ respectively). This can be explained by the fact that in the present study we investigated eosinophilic inflammation in blood rather than sputum, by the smaller study population (60 vs. 120 patients (1)) and the non-parametric distribution due to the high number of non-responders, especially to AMP. Alternatively, differences in smoking behavior of the subjects may have played a role. Smoking has been shown to blunt eosinophilic inflammation, demonstrated by lower numbers of eosinophils in sputum and blood of smokers and ex-smokers compared to never-smokers (11). Further studies in never-smokers are therefore warranted.

In conclusion, we have shown that bronchial provocation with dry powder adenosine is a suitable alternative to provocation with nebulized AMP, considering the good agreement between the tests and comparable baseline predictors. Moreover, dry powder adenosine appears to offer an improvement over nebulized AMP, because of its higher sensitivity for less hyperresponsive subjects with asthma.

Acknowledgments

We thank Anne H. de Boer and Prof. Dirkje S. Postma (University of Groningen) for their significant scientific contributions to this work.

References

1. Van den Berge M, Meijer RJ, Kerstjens HAM, de Reus DM, Koeter GH, Kauffman HF, et al. PC(20) adenosine 5'-monophosphate is more closely associated with airway inflammation in asthma than PC(20) methacholine. *Am J Respir Crit Care Med*. 2002;165(5):1546–50.
2. Prosperini G, Rajakulasingam K, Cacciola RR, Spicuzza L, Rorke S, Holgate ST, et al. Changes in sputum counts and airway hyperresponsiveness after budesonide: monitoring anti-inflammatory response on the basis of surrogate markers of airway inflammation. *J Allergy Clin Immunol*. 2002;110(6):855–61.
3. Choi SH, Kim DK, Yu J, Yoo Y, Koh YY. Bronchial responsiveness to methacholine and adenosine 5'-monophosphate in young children with asthma: their relationship with blood eosinophils and serum eosinophil cationic protein. *Allergy*. 2007;62(10):1119–24.
4. Prieto L, Reig I, Rojas R, Ferrer A, Domenech J. The effect of challenge method on sensitivity and reactivity to adenosine 5'-monophosphate in subjects with suspected asthma. *Chest*. 2006;130(5):1448–53.

5. Cohen J, Postma DS, Douma WR, Vonk JM, de Boer AH, ten Hacken NHT. Particle size matters: diagnostics and treatment of small airways involvement in asthma. *Eur Respir J*. 2011;37(3):532–40.
6. Lexmond AJ, van der Wiel E, Hagedoorn P, Bult W, Frijlink HW, ten Hacken NHT, et al. Adenosine dry powder inhalation for bronchial challenge testing, part 2: Proof of concept in asthmatic subjects. *Eur J Pharm Biopharm*. 2014;88:148–52.
7. Lexmond AJ, Hagedoorn P, van der Wiel E, ten Hacken NHT, Frijlink HW, de Boer AH. Adenosine dry powder inhalation for bronchial challenge testing, part 1: Inhaler and formulation development and in vitro performance testing. *Eur J Pharm Biopharm*. 2014;86(1):105–14.
8. Daxun Z, Rafferty P, Richards R, Summerell S, Holgate ST. Airway refractoriness to adenosine 5'-monophosphate after repeated inhalation. *J Allergy Clin Immunol*. 1989;83:152–8.
9. Singh D, Fairwood J, Murdoch R, Weeks A, Russell P, Roy K, et al. The reproducibility of adenosine monophosphate bronchial challenges in mild, steroid-naive asthmatics. *Br J Clin Pharmacol*. 2008;66(2):261–5.
10. Brannan JD, Anderson SD, Perry CP, Freed-Martens R, Lassig AR, Charlton B. The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline. *Respir Res*. 2005;6:144.
11. Telenga ED, Kerstjens HAM, ten Hacken NHT, Postma DS, van den Berge M. Inflammation and corticosteroid responsiveness in ex-, current- and never-smoking asthmatics. *BMC Pulm Med*. 2013;13(1):58.

Figure 1: (A) Comparison of the PC₂₀ AMP and PD₂₀ adenosine. The lines indicate the geometric means, * depicts negative test results, which were censored to PC₂₀ AMP = 640 mg/mL and PD₂₀ adenosine = 160 mg in the analyses. (B) Correlation analysis between PC₂₀ AMP and PD₂₀ adenosine, showing a strongly significant correlation between the two test results ($r_{Sp} = 0.799$, $p < 0.001$).

Table 1: Baseline predictors for PC₂₀ AMP and PD₂₀ adenosine obtained by multiple linear regression analysis.

Dependent variable	Baseline predictor	B	CI 95%	<i>p</i> -value	R ²
log₂ PC₂₀ AMP	Age (years)	0.111	0.035; 0.187	0.005	0.34
	Smoking status	-0.028	-1.82; 1.77	0.98	
	Eos blood (% total)	-0.306	-0.686; 0.074	0.11	
	FEV ₁ (%pred)	0.047	-0.011; 0.104	0.11	
	RV (%pred)	-0.018	-0.054; 0.017	0.31	
	S _{cond} (/L)	-1.94	-42.1; 38.2	0.92	
log₂ PD₂₀ Adenosine	Age (years)	0.059	0.007; 0.112	0.027	0.30
	Eos blood (% total)	-0.244	-0.542; 0.055	0.11	
	FEV ₁ (%pred)	0.052	0.009; 0.096	0.020	
	RV (%pred)	-0.024	-0.050; 0.002	0.073	

PC₂₀: provocative concentration causing a 20% drop in FEV₁; PD₂₀: provocative dose causing a 20% drop in FEV₁; Eos blood: blood eosinophils as percentage of total leukocytes; FEV₁: forced expiratory volume in 1 s; RV: residual volume; S_{cond}: ventilation heterogeneity of the conductive lung zone.




Figure 1: (A) Comparison of the PC₂₀ AMP and PD₂₀ adenosine. The lines indicate the geometric means, * depicts negative test results, which were censored to PC₂₀ AMP = 640 mg/mL and PD₂₀ adenosine = 160 mg in the analyses. (B) Correlation analysis between PC₂₀ AMP and PD₂₀ adenosine, showing a strongly significant correlation between the two test results ($r_{sp} = 0.799$, $p < 0.001$).

164x92mm (300 x 300 DPI)